| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 0.02 | 100.0% | 33.3% |
| Total Income | 0.02 | 100.0% | 33.3% |
| Expenditure | 37.27 | 20.9% | 26.3% |
| PBT | — | ||
| Net Profit | -38.85 | 9.0% | 12.8% |
| OPM | — | ||
| NPM | — | ||
| EPS | -2.13 | 26.3% | 1152.9% |
Lyell Immunopharma Reports Financial Results for Quarter Ended September 30, 2025
04 May 2026 · 4 May, 7:21 am
Summary
Lyell Immunopharma, Inc. issued a press release on November 12, 2025, announcing its financial results for the quarter ended September 30, 2025. The press release, attached as Exhibit 99.1, contains information regarding the company's financial performance. Specific details and metrics can be found within the exhibit.
Key Highlights
- 1
Lyell Immunopharma, Inc. announced its financial results for the quarter ended September 30, 2025.
- 2
The press release details the company's financial performance for the specified period.
- 3
Further details regarding specific financial metrics would be available in the attached exhibit.
Informational and educational content only. Not investment advice.